At a glance
ClinicalIndex Comparison RecordN/ACompleted· 101 enrolled
Drug / intervention
nintedanib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Non-Interventional Study (NIS) Collecting Experiences For IPF in Taiwan
In Brief
An observational study evaluating nintedanib and pirfenidone for Pulmonary Fibrosis. Completed, enrolled 101 participants across 10 sites.
Detailed Summary
This is a non-interventional, multi-center study to collect data from patients with idiopathic pulmonary fibrosis (IPF) in clinical practice in Taiwan. The study will be carried out at 10 medical centers, the expert centers where IPF patients are mainly managed in Taiwan.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Fibrosis
CountriesTaiwan
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
First PostedAug 2017
Enrollment StartAug 2017
Primary CompletionFeb 2020
TodayJul 2026
First PostedAug 8, 2017
Enrollment StartAug 17, 2017
Primary CompletionFeb 18, 2020
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 8.9 years ago
Interventions
nintedanibdrug
Drug
pirfenidonedrug
Drug